Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alvin Farrel

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Frontiers in Immunology|April 8, 2020
Immunogenicity and Immune Silence in Human CancerMark Yarmarkovich, Alvin Farrel, Artemio Sison, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targetsNathan M Kendsersky, Michal Odrobina, Nathaniel W Mabe, et al.
Neuro-Oncology|January 18, 2025
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targetsNathan M Kendsersky, Michal Odrobina, Nathaniel W Mabe, et al.
Pediatric Blood & Cancer|April 21, 2020
Limited antitumor activity of combined BET and MEK inhibition in neuroblastomaJason R Healy, Lori S Hart, Alexander L Shazad, et al.
Cancer Research Communications|November 16, 2022
Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastomaKateryna Krytska, Colleen E Casey, Jennifer Pogoriler, et al.
Journal for Immunotherapy of Cancer|December 8, 2019
Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibitionJulie Voeller, Amy K Erbe, Jacob Slowinski, et al.
Molecular Cancer Therapeutics|February 5, 2025
Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastomaSmita Matkar, Michael P East, Timothy J Stuhlmiller, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Structural principles of peptide-centric Chimeric Antigen Receptor recognition guide therapeutic expansionYi Sun, Tyler J Florio, Sagar Gupta, et al.
Science Immunology|December 1, 2023
Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansionYi Sun, Tyler J Florio, Sagar Gupta, et al.
Cell Reports|March 7, 2024
ALK upregulates POSTN and WNT signaling to drive neuroblastomaMiller Huang, Wanqi Fang, Alvin Farrel, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|April 8, 2020
Immunogenicity and Immune Silence in Human CancerMark Yarmarkovich, Alvin Farrel, Artemio Sison, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targetsNathan M Kendsersky, Michal Odrobina, Nathaniel W Mabe, et al.
Neuro-Oncology|January 18, 2025
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targetsNathan M Kendsersky, Michal Odrobina, Nathaniel W Mabe, et al.
Pediatric Blood & Cancer|April 21, 2020
Limited antitumor activity of combined BET and MEK inhibition in neuroblastomaJason R Healy, Lori S Hart, Alexander L Shazad, et al.
Cancer Research Communications|November 16, 2022
Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastomaKateryna Krytska, Colleen E Casey, Jennifer Pogoriler, et al.
Journal for Immunotherapy of Cancer|December 8, 2019
Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibitionJulie Voeller, Amy K Erbe, Jacob Slowinski, et al.
Molecular Cancer Therapeutics|February 5, 2025
Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastomaSmita Matkar, Michael P East, Timothy J Stuhlmiller, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Structural principles of peptide-centric Chimeric Antigen Receptor recognition guide therapeutic expansionYi Sun, Tyler J Florio, Sagar Gupta, et al.
Science Immunology|December 1, 2023
Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansionYi Sun, Tyler J Florio, Sagar Gupta, et al.
Cell Reports|March 7, 2024
ALK upregulates POSTN and WNT signaling to drive neuroblastomaMiller Huang, Wanqi Fang, Alvin Farrel, et al.
Pageof 4